| Rekha Vijayan, MD | |
|
301 E Saint Joseph St, Green Bay, WI 54301-2241 | |
| (920) 445-7222 | |
| (920) 445-7289 |
| Full Name | Rekha Vijayan |
|---|---|
| Gender | Female |
| Speciality | Psychiatry |
| Experience | 24 Years |
| Location | 301 E Saint Joseph St, Green Bay, Wisconsin |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730406836 | NPI | - | NPPES |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Bellin Psychiatric Center Inc | 4486551058 | 60 |
News Archive
Genetically engineering viruses to carry a suicide gene into ovarian cancer cells could become a potent way to tackle the disease, a leading Cancer Research UK scientist reveals at a conference in Glasgow today (Tuesday).
Lithera, Inc. today announced receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application broadly covering compositions and methods of use associated with LIPO-102, its novel injectable combination of salmeterol xinafoate (SX) and fluticasone propionate (FP) for selective, non-ablative fat reduction.
A Czech study compared two anti-clotting treatment regimens, currently used before coronary angiography / angioplasty to find the optimal balance between preventing ischemic versus bleeding complications of these procedures. The study was conducted in five Czech tertiary cardiology centers.
A study by researchers at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) has discovered how tamoxifen-resistant breast-cancer cells grow and proliferate.
Regulus Therapeutics Inc. today announced the establishment of a new collaboration with GlaxoSmithKline (GSK) to develop and commercialize microRNA therapeutics targeting microRNA-122 in all fields with Hepatitis C Viral infection (HCV) as the lead indication. Under the terms of the new collaboration, Regulus will receive additional upfront and early-stage milestone payments with the potential to earn more than $150 million in miR-122-related combined payments, and tiered royalties up to double digits on worldwide sales of products.
› Verified 8 days ago
| Entity Name | Bellin Psychiatric Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952554800 PECOS PAC ID: 4486551058 Enrollment ID: O20031212000884 |
News Archive
Genetically engineering viruses to carry a suicide gene into ovarian cancer cells could become a potent way to tackle the disease, a leading Cancer Research UK scientist reveals at a conference in Glasgow today (Tuesday).
Lithera, Inc. today announced receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application broadly covering compositions and methods of use associated with LIPO-102, its novel injectable combination of salmeterol xinafoate (SX) and fluticasone propionate (FP) for selective, non-ablative fat reduction.
A Czech study compared two anti-clotting treatment regimens, currently used before coronary angiography / angioplasty to find the optimal balance between preventing ischemic versus bleeding complications of these procedures. The study was conducted in five Czech tertiary cardiology centers.
A study by researchers at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) has discovered how tamoxifen-resistant breast-cancer cells grow and proliferate.
Regulus Therapeutics Inc. today announced the establishment of a new collaboration with GlaxoSmithKline (GSK) to develop and commercialize microRNA therapeutics targeting microRNA-122 in all fields with Hepatitis C Viral infection (HCV) as the lead indication. Under the terms of the new collaboration, Regulus will receive additional upfront and early-stage milestone payments with the potential to earn more than $150 million in miR-122-related combined payments, and tiered royalties up to double digits on worldwide sales of products.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Rekha Vijayan, MD Po Box 22040, Green Bay, WI 54305-2040 Ph: (920) 445-7222 | Rekha Vijayan, MD 301 E Saint Joseph St, Green Bay, WI 54301-2241 Ph: (920) 445-7222 |
News Archive
Genetically engineering viruses to carry a suicide gene into ovarian cancer cells could become a potent way to tackle the disease, a leading Cancer Research UK scientist reveals at a conference in Glasgow today (Tuesday).
Lithera, Inc. today announced receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application broadly covering compositions and methods of use associated with LIPO-102, its novel injectable combination of salmeterol xinafoate (SX) and fluticasone propionate (FP) for selective, non-ablative fat reduction.
A Czech study compared two anti-clotting treatment regimens, currently used before coronary angiography / angioplasty to find the optimal balance between preventing ischemic versus bleeding complications of these procedures. The study was conducted in five Czech tertiary cardiology centers.
A study by researchers at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) has discovered how tamoxifen-resistant breast-cancer cells grow and proliferate.
Regulus Therapeutics Inc. today announced the establishment of a new collaboration with GlaxoSmithKline (GSK) to develop and commercialize microRNA therapeutics targeting microRNA-122 in all fields with Hepatitis C Viral infection (HCV) as the lead indication. Under the terms of the new collaboration, Regulus will receive additional upfront and early-stage milestone payments with the potential to earn more than $150 million in miR-122-related combined payments, and tiered royalties up to double digits on worldwide sales of products.
› Verified 8 days ago
Dr. Emily R Rademacher, D.O., M.B.A. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 301 E Saint Joseph St, Green Bay, WI 54301 Phone: 920-433-3630 Fax: 920-437-0533 | |
Dr. George D Soncrant, DO Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 3000 Riverside Dr, Suite 180, Green Bay, WI 54301 Phone: 920-632-7040 Fax: 920-632-7262 | |
Dr. Aubree Rae Bruhnding, DO Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 725 S Webster Ave Ste 201, Green Bay, WI 54301 Phone: 920-430-7100 Fax: 920-430-7114 | |
John Christopher Charles, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 301 E Saint Joseph St, Green Bay, WI 54301 Phone: 920-433-6073 | |
Dr. David K Kaufman, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 725 S Webster Ave, Suite 201, Green Bay, WI 54301 Phone: 920-430-7100 Fax: 920-430-7114 | |
Dr. Anne Marie Wannamaker, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 301 E Saint Joseph St, Green Bay, WI 54301 Phone: 920-433-3630 Fax: 920-431-0333 | |
Veeranagouda Patil, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2640 W Point Rd, Green Bay, WI 54304 Phone: 920-490-3790 Fax: 920-490-3858 |